STOCK TITAN

Bluejay Diagnostics Inc - BJDX STOCK NEWS

Welcome to our dedicated page for Bluejay Diagnostics news (Ticker: BJDX), a resource for investors and traders seeking the latest updates and insights on Bluejay Diagnostics stock.

Bluejay Diagnostics Inc (BJDX) is a pioneer in rapid sepsis detection through its innovative Symphony™ platform, delivering critical IL-6 biomarker results in emergency care settings. This dedicated news hub provides investors and healthcare professionals with essential updates on regulatory milestones, clinical validations, and strategic partnerships.

Access authoritative information about BJDX's progress in transforming critical care diagnostics, including earnings reports, product development timelines, and peer-reviewed study outcomes. Our curated news collection simplifies tracking of FDA clearances, technology enhancements, and market expansion initiatives relevant to near-patient testing solutions.

Key updates include developments in sepsis triage protocols, Symphony platform deployments, and clinical utility studies demonstrating IL-6's prognostic value. Bookmark this page for real-time notifications about BJDX's advancements in cost-effective rapid diagnostics that support time-sensitive treatment decisions.

Rhea-AI Summary

Bluejay Diagnostics (NASDAQ: BJDX) has announced the acceptance of an abstract for presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual Meeting in Philadelphia. The presentation will showcase new clinical data from the SYMON-I study, which evaluated the Symphony IL-6 Test in sepsis patients.

The study assessed IL-6 as a prognostic indicator for 28-day mortality, 7-day mortality, and microbiological positivity in patients intended or admitted to intensive care units. Dr. Nathan Shapiro from Beth Israel Deaconess Medical Center highlighted that early IL-6 testing shows promise in predicting short-term and mid-term mortality in sepsis patients.

The company is currently conducting the SYMON-II validation clinical study to further establish IL-6 as a prognostic biomarker. The presentation, titled 'Multicenter Symphony IL-6 Monitoring Sepsis ICU Validation Study (SYMON I)', will be delivered by Dr. John H. Lee and Dr. Nathan Shapiro on May 14, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
none
-
Rhea-AI Summary

Bluejay Diagnostics (NASDAQ: BJDX) has announced a warrant inducement transaction that will generate approximately $3.7 million in gross proceeds. The agreement involves institutional investors who are existing warrant holders exercising their rights to purchase up to 1,085,106 shares of common stock at a reduced exercise price of $3.42 per share.

In exchange for exercising their existing warrants, investors will receive new warrants to purchase an additional 1,085,106 shares of common stock. These new warrants are immediately exercisable at $3.42 per share and will expire in five years. The transaction was facilitated by Aegis Capital Corp. as the exclusive financial advisor, with legal counsel provided by Hogan Lovells US LLP for Bluejay and Kaufman & Canoles, P.C. for Aegis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-60.67%
Tags
none
-
Rhea-AI Summary

Bluejay Diagnostics (NASDAQ: BJDX) has announced a 1-for-50 reverse stock split effective November 18, 2024. The split will reduce outstanding common stock from approximately 27,624,740 shares to 552,854 shares. Trading will continue under the symbol 'BJDX' with a new CUSIP number 095633509. Stockholders will receive cash payments for fractional shares, and the split will proportionally adjust all outstanding equity awards and warrants. The company's transfer agent, Continental Stock Transfer & Trust Company, will manage the exchange process.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-28.85%
Tags
Rhea-AI Summary

Bluejay Diagnostics (NASDAQ: BJDX) has announced the closing of its $8.75 million underwritten public offering, completed on June 28, 2024.

This offering included 5,368,098 Common Units or Prefunded Units, each priced at $1.63 and $1.6299 respectively. The proceeds will be used to repay $2.3 million in outstanding debt and to fund FDA approval processes and general working capital needs.

This offering includes several warrant types, such as Class C and Class D Warrants, which have specific exercise prices and expiration terms. Aegis Capital Corp. acted as the underwriter, and the offering was made under SEC registration statement Form S-1.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.8%
Tags
-
Rhea-AI Summary

Bluejay Diagnostics (NASDAQ: BJDX) announced the pricing of an $8.75 million underwritten public offering. The offering includes 5,368,098 Common Units or Prefunded Units, each with one share of common stock or one pre-funded warrant and three types of warrants for additional stock purchases. The company set the purchase price for Common Units at $1.63 and Prefunded Units at $1.6299. Proceeds will be used to repay $2.3 million of outstanding debt, fund FDA approval-related activities, and support R&D and working capital. The offering is expected to close on June 28, 2024, with Aegis Capital Corp. as the underwriter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-53.99%
Tags
-
Rhea-AI Summary

Bluejay Diagnostics announced the primary results of their SYMON-I pilot clinical study, which suggests that interleukin-6 (IL-6) can predict mortality in sepsis and septic shock patients within 28 days of ICU admission. The study compared IL-6 levels to standard clinical tests like lactate and SOFA, finding IL-6 to be a more reliable predictor of mortality. The results will be validated in the SYMON-II study set to begin in Q3 2024. Positive results from SYMON-II could support a 510(k) application to the FDA in 2025. The company aims to present these results at scientific meetings and publish them in peer-reviewed journals, contingent on raising additional capital.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-40.73%
Tags
none
Rhea-AI Summary

Bluejay Diagnostics announced a 1-for-8 reverse stock split effective June 20, 2024. This will reduce outstanding shares from approximately 4.5 million to around 564,000, with no change in par value. Fractional shares will be compensated in cash. The stock will trade under the same symbol, BJDX, but with a new CUSIP number. The reverse split affects all shareholders uniformly, preserving their percentage ownership except for fractional share adjustments. The transfer agent for this process is Continental Stock Transfer & Trust Company. Bluejay focuses on rapid diagnostics to improve patient outcomes in critical care settings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.39%
Tags
-
Rhea-AI Summary
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) announced the closing of a public offering of 2,692,308 shares of common stock and warrants, generating approximately $3.5 million in gross proceeds. The company intends to use the net proceeds for obtaining FDA approval, clinical studies, research and development, and general working capital needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.36%
Tags
-
Rhea-AI Summary
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) announced the pricing of a public offering of 2,692,308 shares of common stock and warrants to purchase up to 2,692,308 shares at a combined offering price of $1.30 per share. The offering is expected to close on December 28, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.48%
Tags
Rhea-AI Summary
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) announces the initiation of a multicenter clinical study to evaluate the Symphony IL-6 test in sepsis patients, positioning the company to move forward with multiple initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.5%
Tags
Bluejay Diagnostics Inc

Nasdaq:BJDX

BJDX Rankings

BJDX Stock Data

2.11M
1.23M
0.69%
6.7%
5.43%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
ACTON